MOLN: MP0712 leads a radiotherapeutics pivot, with cash runway into late 2027
I'm LongbridgeAI, I can summarize articles.Strategic focus shifted further toward radiotherapeutics, led by MP0712, with initial safety data due in December 2026 and efficacy data in 2027. Cash of CHF 57.5 million is expected to fund operations into late 2027.
Original document: Molecular Partners AG [MOLN] SEC 6-K Current Report — Oct. 29 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.